# US 2010/0166867 A1 · Novel administration form of osteogenic protein complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166867 A1
- Document ID: US20100166867A1
- Status: Published application
- Kind: A1
- Application number: 12/591,442
- Filed: 2009-11-19
- Published: 2010-07-01
- Earliest claimed: 2008-11-19
- Assignees: Adocia
- Inventors: Olivier SOULA; Remi SOULA; Gerard SOULA
- Web page: https://patentgrep.com/patent/US20100166867A1

## CPC

- A61K 31/721: Dextrans
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/143: {with inorganic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/42: Phosphorus; Compounds thereof
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 47/02: Inorganic compounds
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 19/00: Drugs for skeletal disorders
- C08B 37/0021: {Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran}
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/414: Growth factors
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

The invention relates to osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, said coprecipitate being in divided form. The invention also relates to kits for performing the invention. The invention also relates to the process for preparing the coprecipitate in divided form, containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products and medical devices comprising said coprecipitate.

## Claims

### Claim 1

A coprecipitate consisting of at least one complex between an osteogenic protein and an anionic polysaccharide in its insolubilized form and at least one insoluble calcium salt, said coprecipitate being in divided form.

### Claim 2 (depends on 1)

The coprecipitate as claimed in claim 1, in which the insoluble calcium salt is chosen from the group consisting of calcium orthophosphates in anhydrous or hydrated form, alone or as a mixture.

### Claim 3 (depends on 1)

The coprecipitate as claimed in claim 1, which also comprises at least one insoluble calcium salt chosen from the group consisting of calcium oxalate, calcium ascorbate, calcium carbonate and calcium sulfate.

### Claim 4 (depends on 1)

The coprecipitate as claimed in claim 1, in which the insoluble calcium salt is chosen from the group consisting of mixed salts formed between cationic calcium ions and anionic ions such as mono-, di- or tribasic phosphates, polysaccharide carboxylates, carbonates, hydroxides and the possible anions borne by bases.

### Claim 5 (depends on 1)

The coprecipitate as claimed in claim 1, which also comprises at least one growth factor with chemo-attracting and angiogenic power.

### Claim 6 (depends on 1)

The coprecipitate as claimed in claim 1, wherein the anionic polysaccharide is chosen from the group consisting of polysaccharides functionalized with hydrophobic derivatives.

### Claim 7 (depends on 1)

The coprecipitate as claimed in claim 1, wherein the anionic polysaccharide is chosen from the group consisting of polysaccharides comprising carboxyl functional groups partly substituted with hydrophobic alcohols, of general formula IX:
in which q represents the mole fraction of carboxyl functions of the polysaccharide that are substituted with F-R-G-Ah and is between 0.01 and 0.7,
F′ being an amide function,
G being an ester, thioester, carbonate or carbamate function,
R being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, optionally comprising one or more heteroatoms such as O, N and/or S, and having at least one acid function,
Ah being a hydrophobic alcohol residue, produced by coupling between the hydroxyl function of the hydrophobic alcohol and at least one electrophilic function borne by the group R,
when the carboxyl function of the polysaccharide is not substituted with F′ R G Ah, then the carboxyl functional group(s) of the polysaccharide are carboxylates of a cation,
said polysaccharide comprising carboxyl functional groups being amphiphilic at neutral pH.

### Claim 8 (depends on 1)

The coprecipitate as claimed in claim 1, wherein the polysaccharides comprising carboxyl functional groups are synthetic polysaccharides obtained from polysaccharides naturally comprising carboxyl functional groups or from neutral polysaccharides on which at least 15 carboxyl functional groups per 100 saccharide units have been grafted, of general formula X:
the natural polysaccharides being chosen from the group of polysaccharides mainly consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type,
L being a bond resulting from coupling between the linker Q and an OH function of the polysaccharide, and being either an ester, thioester, carbonate, carbamate or ether function,
r represents the mole fraction of the substituents L Q per saccharide unit of the polysaccharide,
Q being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, such as O, N and/or S, and comprising at least one carboxyl functional group, CO2H.

### Claim 9 (depends on 1)

The coprecipitate as claimed in claim 1, wherein the anionic polysaccharide is chosen from the group consisting of anionic polysaccharides mainly comprising glycoside bonds of (1,4), (1,3) and/or (1,2) type, functionalized with at least one tryptophan derivative corresponding to the general formula I below:
the polysaccharide being consisted mainly of glycoside bonds of (1,4) and/or (1,3) and/or (1,2) type,
F resulting from coupling between the linker R and an —OH function of the neutral or anionic polysaccharide, being either an ester, thioester, amide, carbonate, carbamate, ether, thioether or amine function,
R being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, such as O, N and/or S, and having at least one acid function,
Trp being a residue of a tryptophan derivative, L or D, produced by coupling between the amine of the tryptophan derivative and the at least one acid borne by the group R and/or an acid borne by the anionic polysaccharide,
n represents the mole fraction of the groups R substituted with Trp and is between 0.05 and 0.7,
o represents the mole fraction of the acid functions of the polysaccharides that are substituted with Trp and is between 0.05 and 0.7,
i represents the mole fraction of acid functions borne by the group R per saccharide unit and is between 0 and 2,
j represents the mole fraction of acid functions borne by the anionic polysaccharide per saccharide unit and is between 0 and 1,
(i+j) represents the mole fraction of acid functions per saccharide unit and is between 0.1 and 2,
when R is not substituted with Trp, then the acid(s) of the group R are carboxylates of a cation,
when the polysaccharide is an anionic polysaccharide, when one or more acid functions of the polysaccharide are not substituted with Trp, then they are salified with a cation,
said polysaccharides being amphiphilic at neutral pH.

### Claim 10 (depends on 1)

The coprecipitate as claimed in claim 1, wherein in that the anionic polysaccharide is chosen from the group consisting of the functionalized anionic polysaccharides of general formula III below:
R being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, such as O, N and/or S, and having at least one acid function,
F resulting from the coupling between the linker R and an —OH function of the neutral or anionic polysaccharide, being either an ester, thioester, amide, carbonate, carbamate, ether, thioether or amine function,
AA being a hydrophobic amino acid residue, L or D, produced by the coupling between the amine of the amino acid and an acid borne by the group R, said hydrophobic amino acid being chosen from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide and 2 indolethylamine, and salts thereof of an alkali metal cation, or chosen from phenylalanine, leucine, isoleucine and valine, and alcohol, amide or decarboxylated derivatives thereof.
t represents the mole fraction of the substituent F R [AA]n per glycoside unit, and is between 0.1 and 2,
p represents the mole fraction of groups R substituted with AA and is between 0.05 and 1.
When R is not substituted by AA, then the acid(s) of the group R are carboxylates of a cation.

### Claim 11 (depends on 1)

The coprecipitate as claimed in claim 1, in which the osteogenic protein is chosen from the group consisting of BMP-2 (dibotermine-alpha), BMP-4, BMP 7 (eptotermine-alpha), BMP-14 and GDF 5, alone or in combination.

### Claim 12 (depends on 5)

The coprecipitate as claimed in claim 5, in which the at least one growth factor with chemo-attracting and angiogenic power is PDGF.

### Claim 13 (depends on 6)

The coprecipitate as claimed in claim 6, which comprises at least BMP-2 and PDGF-BB.

### Claim 14 (depends on 6)

The coprecipitate as claimed in claim 6, which comprises at least BMP-7 and PDGF-BB.

### Claim 15 (depends on 6)

The coprecipitate as claimed in claim 6, which comprises at least GDF-5 and PDGF-BB.

### Claim 16 (depends on 6)

The coprecipitate as claimed in claim 6, in which the osteogenic protein is chosen from the group formed by BMP-2 (dibotermine-alpha), BMP-4, BMP 7 (eptotermine-alpha), BMP-14 and GDF-5, alone or in combination, and the at least one growth factor with chemo-attracting and angiogenic power is VEGF.

### Claim 17

A kit for preparing an osteogenic implant, comprising at least:
a—a composition comprising at least one osteogenic protein,
b—a composition comprising at least one polysaccharide,
c—a composition comprising at least one soluble calcium salt,
a composition comprising at least one soluble salt of an anion capable of forming an insoluble calcium salt.

### Claim 18 (depends on 17)

The kit as claimed in claim 17, also comprising an additional composition comprising at least one base.

### Claim 19 (depends on 18)

The kit as claimed in claim 18, also comprising a second base that may be added to compositions b, c or d.

### Claim 20 (depends on 17)

The kit as claimed in claim 17, in which the composition comprising the osteogenic protein may also comprise the polysaccharide for forming the complex.

### Claim 21 (depends on 17)

The kit as claimed in claim 17, in which the composition comprising the complex may also comprise the soluble salt of an anion capable of forming an insoluble calcium salt and/or a base.

### Claim 22 (depends on 17)

The kit as claimed in claim 17, in which the composition comprising the polysaccharide may also comprise the soluble salt of an anion capable of forming an insoluble calcium salt and/or a base.

### Claim 23 (depends on 17)

The kit as claimed in claim 17, in which the composition comprising the soluble calcium salt may also comprise a base.

### Claim 24

A kit comprising:
a—a composition comprising at least one osteogenic protein,
b—a composition comprising at least one anionic polysaccharide, at least one base and at least one soluble salt of an anion capable of forming an insoluble calcium salt,
c—a composition comprising at least one soluble calcium salt.

### Claim 25

A kit comprising:
a—a composition comprising at least one osteogenic protein,
b—a composition comprising at least one anionic polysaccharide and at least one soluble salt of an anion capable of forming an insoluble calcium salt,
c—a composition comprising at least one soluble calcium salt and at least one base.

### Claim 26 (depends on 17)

The kit as claimed in claim 17, wherein the anionic polysaccharide is chosen from the group consisting of polysaccharides functionalized with hydrophobic derivatives.

### Claim 27 (depends on 26)

The kit as claimed in claim 26, wherein the anionic polysaccharide is chosen from the group consisting of polysaccharides comprising carboxyl functional groups partly substituted with hydrophobic alcohols, of general formula IX:
in which q represents the mole fraction of carboxyl functions of the polysaccharide that are substituted with F-R-G-Ah and is between 0.01 and 0.7,
F′ being an amide function,
G being an ester, thioester, carbonate or carbamate function,
R being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, optionally comprising one or more heteroatoms such as O, N and/or S, and having at least one acid function,
Ah being a hydrophobic alcohol residue, produced by coupling between the hydroxyl function of the hydrophobic alcohol and at least one electrophilic function borne by the group R,
when the carboxyl function of the polysaccharide is not substituted with F′ R G Ah, then the carboxyl functional group(s) of the polysaccharide are carboxylates of a cation,
said polysaccharide comprising carboxyl functional groups being amphiphilic at neutral pH.

### Claim 28 (depends on 26)

The kit as claimed in claim 26, wherein the polysaccharides comprising carboxyl functional groups are synthetic polysaccharides obtained from polysaccharides naturally comprising carboxyl functional groups or from neutral polysaccharides on which at least 15 carboxyl functional groups per 100 saccharide units have been grafted, of general formula X:
the natural polysaccharides being chosen from the group of polysaccharides mainly consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type,
L being a bond resulting from coupling between the linker Q and an OH function of the polysaccharide, and being either an ester, thioester, carbonate, carbamate or ether function,
r represents the mole fraction of the substituents L Q per saccharide unit of the polysaccharide,
Q being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, such as O, N and/or S, and comprising at least one carboxyl functional group, CO2H.

### Claim 29 (depends on 26)

The kit as claimed in claim 26, wherein the anionic polysaccharide is chosen from the group consisting of anionic polysaccharides mainly comprising glycoside bonds of (1,4), (1,3) and/or (1,2) type, functionalized with at least one tryptophan derivative corresponding to the general formula I below:
the polysaccharide being consisted mainly of glycoside bonds of (1,4) and/or (1,3) and/or (1,2) type,
F resulting from coupling between the linker R and an —OH function of the neutral or anionic polysaccharide, being either an ester, thioester, amide, carbonate, carbamate, ether, thioether or amine function,
R being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, such as O, N and/or S, and having at least one acid function,
Trp being a residue of a tryptophan derivative, L or D, produced by coupling between the amine of the tryptophan derivative and the at least one acid borne by the group R and/or an acid borne by the anionic polysaccharide,
n represents the mole fraction of the groups R substituted with Trp and is between 0.05 and 0.7,
o represents the mole fraction of the acid functions of the polysaccharides that are substituted with Trp and is between 0.05 and 0.7,
i represents the mole fraction of acid functions borne by the group R per saccharide unit and is between 0 and 2,
j represents the mole fraction of acid functions borne by the anionic polysaccharide per saccharide unit and is between 0 and 1,
(i+j) represents the mole fraction of acid functions per saccharide unit and is between 0.1 and 2,
when R is not substituted with Trp, then the acid(s) of the group R are carboxylates of a cation,
when the polysaccharide is an anionic polysaccharide, when one or more acid functions of the polysaccharide are not substituted with Trp, then they are salified with a cation,
said polysaccharides being amphiphilic at neutral pH.

### Claim 30 (depends on 26)

The kit as claimed in claim 26, wherein the anionic polysaccharide is chosen from the group consisting of the functionalized anionic polysaccharides of general formula III below:
R being a chain comprising between 1 and 18 carbons, optionally branched and/or unsaturated, comprising one or more heteroatoms, such as O, N and/or S, and having at least one acid function,
F resulting from the coupling between the linker R and an —OH function of the neutral or anionic polysaccharide, being either an ester, thioester, amide, carbonate, carbamate, ether, thioether or amine function,
AA being a hydrophobic amino acid residue, L or D, produced by the coupling between the amine of the amino acid and an acid borne by the group R, said hydrophobic amino acid being chosen from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide and 2 indolethylamine, and salts thereof of an alkali metal cation, or chosen from phenylalanine, leucine, isoleucine and valine, and alcohol, amide or decarboxylated derivatives thereof.
t represents the mole fraction of the substituent F R [AA]n per glycoside unit, and is between 0.1 and 2,
p represents the mole fraction of groups R substituted with AA and is between 0.05 and 1.
When R is not substituted by AA, then the acid(s) of the group R are carboxylates of a cation.

### Claim 31 (depends on 17)

The kit as claimed in claim 17, in which the osteogenic protein is chosen from the group consisting of BMP-2 (dibotermine-alpha), BMP-4, BMP 7 (eptotermine-alpha), BMP-14 and GDF-5, alone or in combination.

### Claim 32 (depends on 17)

The kit as claimed in claim 17, in which the at least one growth factor with chemoattracting and angiogenic power is PDGF.

### Claim 33 (depends on 17)

The kit as claimed in claim 17, which comprises at least BMP 2 and PDGF BB.

### Claim 34 (depends on 17)

The kit as claimed in claim 17, which comprises at least BMP 7 and PDGF BB.

### Claim 35 (depends on 17)

The kit as claimed in claim 17, which comprises at least GDF-5 and PDGF-BB.

### Claim 36 (depends on 17)

The kit as claimed in claim 17, in which the osteogenic protein is chosen from the group consisting of BMP-2 (dibotermine-alpha), BMP-4, BMP 7 (eptotermine-alpha), BMP-14 and GDF-5, alone or in combination, and the at least one growth factor with chemo-attracting and angiogenic power is VEGF.

### Claim 37 (depends on 17)

The kit as claimed in claim 17, in which the soluble calcium salt is chosen from the group consisting of calcium chloride, D gluconate, formate, D-saccharate, acetate, L-lactate, glutamate and aspartate.

### Claim 38 (depends on 17)

The kit as claimed in claim 17, in which the soluble calcium salt is calcium chloride.

### Claim 39 (depends on 17)

The kit as claimed in claim 17, in which the soluble salt of an anion capable of forming a precipitate with the calcium ion is a soluble salt whose anion is chosen from the group consisting of phosphate anions comprising the phosphate ion PO43-, the hydrogen phosphate ion HPO42- and the dihydrogen phosphate ion H2PO4-.

### Claim 40 (depends on 17)

The kit as claimed in claim 17, in which the base is chosen from mineral and organic bases.

### Claim 41 (depends on 40)

The kit as claimed in claim 40, in which the mineral base is chosen from the group consisting of sodium hydroxide, sodium hydrogen carbonate and sodium carbonate.

### Claim 42 (depends on 40)

The kit as claimed in claim 40, in which the organic base is chosen from the group consisting of amines and deprotonated amino acids.

### Claim 43 (depends on 40)

The kit as claimed in claim 40, in which the organic base is chosen from the group consisting of imidazole and derivatives thereof, especially histidine, proline, ethanolamine and serine.

### Claim 44 (depends on 17)

The kit as claimed in claim 17, which also comprises at least one organic matrix or a mineral matrix or a mixed matrix.

### Claim 45 (depends on 44)

The kit as claimed in claim 44, in which the matrix is an organic matrix chosen from the group consisting of hydrogels and/or matrices based on a crosslinked polymer.

### Claim 46 (depends on 45)

The kit as claimed in claim 45, in which the hydrogel is a hydrogel obtained by chemical or physical crosslinking of polymer chains.

### Claim 47 (depends on 45)

The kit as claimed in claim 45, in which the crosslinked polymer is crosslinked and sterilized purified natural collagen.

### Claim 48 (depends on 46)

The kit as claimed in claim 46, in which the hydrogel is chosen from the group of synthetic polymers including copolymers of ethylene glycol and of lactic acid, copolymers of ethylene glycol and of glycolic acid, poly(N vinylpyrrolidone), polyvinylic acids, and polyacrylamides and polyacrylic acids.

### Claim 49 (depends on 45)

The kit as claimed in claim 45, in which the hydrogel is chosen from the group of natural polymers including hyaluronic acid, keratan, pullulan, pectin, dextran, cellulose and cellulose derivatives, alginic acid, xanthan, carrageenan, chitosan, chondroitin, collagen, gelatin, polylysine, fibrin, and biologically acceptable salts thereof.

### Claim 50 (depends on 17)

The kit as claimed in claim 17, in which the compositions constituting the kit are aqueous solutions.

### Claim 51 (depends on 17)

The kit as claimed in claim 17, in which the compositions constituting the kit are lyophilizates.

### Claim 52 (depends on 1)

A process for preparing the coprecipitate as defined in claim 1, which comprises a coprecipitation step obtained by:
precipitating the complex between the anionic polymer and the osteogenic protein by addition of the solution of calcium ion salt,
precipitating the calcium ions by addition of a composition comprising at least one soluble salt of an anion capable of forming an insoluble calcium salt at a given pH, the complex between the anionic polymer and the osteogenic protein complex being obtained by adding the anionic polysaccharide solution to the osteogenic protein solution.

### Claim 53 (depends on 52)

The process as claimed in claim 52, in which the precipitation of the calcium salt takes place in the form of calcium phosphate, by addition of a soluble phosphate solution.
